SCHEMBL1623846

SCHEMBL1623846

Cc1ccc2c(N3CCN(Cc4ccccc4)CC3C(C)C)nc(-c3ccccc3O)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
MAPT P10636 3/20 0.54
TSHR P16473 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
CHEK2 O96017 2/20 0.41
SMAD3 P84022 1/20 0.41
PIK3CA P42336 1/20 0.39
MTOR P42345 1/20 0.39
LMNA P02545 1/20 0.38
ACHE P22303 1/20 0.38
PPARD Q03181 2/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623844 1.00 ALDH1A1 (0.54) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1084556 0.82 ALDH1A1 (0.78) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1083968 0.82 NR1I2 (0.49) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL5504855 0.80 MAPT (0.40) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL12721106 0.79 SMAD3 (0.38) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1621715 0.79 SMAD3 (0.38) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1621719 0.79 SMAD3 (0.38) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1084758 0.79 ALDH1A1 (0.73) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL1623550 0.79 CHEK2 (0.44) ALDH1A1MAPTTSHRL3MBTL1KMT2A
SCHEMBL1623554 0.79 CHEK2 (0.44) ALDH1A1MAPTTSHRL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 ALDH1A1 2907/4885MAPT 2508/4885TSHR 3828/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 ALDH1A1 2907/4885MAPT 2508/4885TSHR 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.